Safety Profile of Once-Weekly Regimen Was comparable opposed to the twice-weekly regimen

Safety Profile of Once-Weekly Regimen Was comparable opposed to the twice-weekly regimen

Annual-Meeting

1 year
91 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Safety Profile of Once-Weekly Regimen Was comparable opposed to the twice-weekly regimen at Annual Meeting 2018
Up Next Autoplay
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
Category: Melanoma and Skin Cancer
9 Views
UVA Cancer Center 2 months
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
Category: Melanoma and Skin Cancer
28 Views
UVA Cancer Center 2 months
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Category: Melanoma and Skin Cancer
40 Views
Cancer-News 2 months
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
35 Views
Cancer-News 3 months
Will the CheckMate 204 data affect clinicians?
Will the CheckMate 204 data affect clinicians?
Category: Melanoma and Skin Cancer
19 Views
moasc 4 months
CheckMate 204 Study
CheckMate 204 Study
Category: Melanoma and Skin Cancer
23 Views
moasc 4 months
Clinicians could change the way they manage their patients
Clinicians could change the way they manage their patients
Category: Melanoma and Skin Cancer
4 Views
moasc 4 months
Fixing toxic therapy
Fixing toxic therapy
Category: Melanoma and Skin Cancer
8 Views
moasc 4 months
Alternate dosing for immunotherapy
Alternate dosing for immunotherapy
Category: Melanoma and Skin Cancer
4 Views
moasc 4 months
Is this data practice changing for clinicians?
Is this data practice changing for clinicians?
Category: Melanoma and Skin Cancer
4 Views
moasc 4 months